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LETTER
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Summary: Initiation of BMP signaling is dependent
upon activation of Type I BMP receptor by constitutively
active Type II BMP receptor. Three Type II BMP recep-
tors have been identified; Acvr2a and Acvr2b serve as
receptors for BMPs and for activin-like ligands whereas
BMPR-II functions only as a BMP receptor. As BMP sig-
naling is required for endochondral ossification and
loss of either Acvr2a or Acvr2b is not associated with
deficits in limb development, we hypothesized that
BMPR-II would be essential for BMP signaling during
skeletogenesis. We removed BMPR-II from early limb
mesoderm by crossing BMPR-II floxed mice with those
carrying the Prx1-Cre transgene. Mice lacking limb
expression of BMPR-II have normal skeletons that
could not be distinguished from control littermates.
From these data, we conclude that BMPR-II is not
required for endochondral ossification in the limb
where loss of BMPR-II may be compensated by BMP
utilization of Acvr2a and Acvr2b. genesis 49:719–724,
2011. VC 2011 Wiley-Liss, Inc.
Signaling by members of the bone morphogenetic
protein (BMP) family has been shown to be critical
for many aspects of limb development and endo-
chondral bone formation. BMPs transduce their sig-
nals by bringing together Type I and II serine/threo-
nine kinase receptors to form heterotetrameric com-
plexes. Within this complex, the constitutively active
kinase domain of the Type II receptor is key to ini-
tiating the BMP signal transduction cascade: its close
proximity to the kinase domain of the Type I recep-
tor promotes Type I receptor phosphorylation
(Shi and Massague, 2003). Once activated, the Type I
receptor is able to phosphorylate and activate BMP-
specific R-Smads, increasing their affinity for Smad4.
The resulting R-Smad/Smad4 complexes travel to
the nucleus where they affect a wide variety of tran-
scriptional responses directly by binding to Smad
binding elements, or indirectly through interactions
with DNA-binding transcription factors and histone-
modifying proteins (Miyazono et al., 2005).
Both too much BMP and too little BMP signaling
result in skeletal abnormalities, consistent with the idea
that BMP signaling is a highly regulated process. While
many investigators have focused on the regulatory roles
of BMPs, BMP antagonists, Type I BMP receptors, and
BMP-specific Smads (Devlin et al., 2003; Kamiya et al.,
2008; Ovchinnikov et al., 2006; Retting et al., 2009;
Selever et al., 2004; Yoon et al., 2005), few studies have
examined the requirement for each of the three Type II
BMP receptors present during skeletogenesis. It has
been reported that global loss of Acvr2a or Acvr2b,
Type II receptors common to both the BMP and activin/
myostatin pathways has no obvious effect on formation
of the embryonic skeleton (Miyazono et al., 2005; Oh
and Li, 1997), allowing us to hypothesize that BMPR-II
is the dominant Type II receptor utilized for skeletogen-
esis. Here we show the surprising result that loss
of BMPR-II in the early limb has no effect on skeletal
patterning or endochondral ossification.
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RESULTS AND DISCUSSION
Deletion of BMPR-II by Prx1-Cre
As global deletion of BMPR-II in mice results in
embryonic lethality during gastrulation (Beppu et al.,
2000), we used Cre recombinase driven by a Prx1
enhancer (Logan et al., 2002) to conditionally remove
BMPR-II from limb mesenchyme. Prx1-Cre heterozy-
gotes were mated with mice homozygous for a condi-
tional allele of BMPR-II engineered by flanking Exons 4
and 5 (which included the transmembrane domain and
a portion of the kinase domain) with lox P sites (Beppu
et al., 2005) to generate BMPR-IICKO mice. We con-
firmed the inactivation of BMPR-II by Prx1-Cre recom-
bination at early limb bud stages using whole mount in
situ hybridization. Figure 1a,b demonstrates the effi-
cient removal of BMPR-II transcripts from the limb mes-
enchyme at E11.5. BMPR-II was still detected in the
limb ectoderm where the Prx1-Cre transgene is inac-
tive. BMPR-II deletion from the limb was further verified
at the protein level by western blot. As illustrated in Fig-
ure 1c, BMPR-II protein in E12 limb bud lysates was sig-
nificantly reduced in the conditional knockout limbs
compared to those of littermate controls.
Loss of BMPR-II Has No Effect on Early Limb
Development
At E11.5, BMPR-IICKO, and Prx1-Cre1 control
embryos were morphologically similar with no appa-
rent differences in the shape, size, or pattern of the
limbs (Fig. 1a,b and data not shown). Detailed histologi-
cal analysis revealed no alterations in the formation or
organization of the developing cartilages at E12.5 in the
absence of BMPR-II (Fig. 1d,e), while quantitative poly-
merase chain reaction (QPCR) analysis of RNA from
E12.5 BMPR-IICKO and control limb buds showed no sig-
nificant changes in early cartilage markers (Sox9 and
Col2a1, data not shown). To assess if loss of BMPR-II
results in changes in BMP signaling, we collected limb
buds from E12 embryos and analyzed them by western
blot for alterations in p-Smad1/5/8 or p-Smad2/3 levels.
As seen in Figure 1f, we found no changes in either
BMP or TGF-b/activin signaling in BMPR-IICKO limbs
when compared to control limbs. Since BMP ligands
FIG. 1. Loss of BMPR-II has no effect on early limb development. (a,b) Whole mount in situ hybridization of E11.5 control and BMPR-IICKO
limb buds showing deletion of BMPR-II from limb mesenchyme. (c) Western blot analysis showing loss of BMPR-II protein in conditional
knockout limbs at E12. b-actin was used as a loading control. (d,e) Alcian blue/Fast red stained sections of forelimb buds of E12.5 control
and BMPR-IICKO embryos. (f) Western blot of extracts from control and BMPR-IICKO E12 limb buds (n 5 3) using anti-pSmad1/5/8 antibody
to evaluate BMP signaling and anti-p-Smad2/3 antibody to evaluate TGF-b signaling. Smad1 and Smad2/3 antibodies were used to detect
total R-Smad protein as a control. (g) Nanostring analysis of E12 limb bud mRNA from control and BMPR-IICKO embryos showing no
changes in the levels of Acvr2a or Acvr2b. Values are expressed as number of molecules per 200 ng of total RNA.
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could utilize Acvr2a and Acv2rb to maintain adequate
signaling levels, we isolated RNA from E12 limb buds
and used the Nanostring nCounter technology (Geiss
et al., 2008) to examine changes in transcript levels for
these receptors. As shown in Figure 1g, no significant
differences were seen in the mRNA levels of Acvr2a or
Acvr2b in BMPR-IICKO limbs. From these data we con-
clude that Acvr2a and Acvr2b present in the early limb
most likely compensate for loss of BMPR-II and are able
to provide the level of BMP signaling necessary for early
skeletogenesis. In addition, these data suggest that
BMPR-II is not uniquely required for the first steps of
limb patterning or early cartilage formation.
Deletion of BMPR-II Results in No Significant
Changes in the Formation of Long Bones
Next we examined BMPR-IICKO mice at later stages of
skeletal development to see if BMPR-II was required for
the subsequent steps of endochondral ossification. Aliz-
arin Red and Alcian Blue-stained skeletons from E15.5
embryos showed no obvious changes in the shape, size,
pattern, or formation of the long bones lacking BMPR-II
(Fig. 2a). These observations were confirmed by histo-
logical analysis of hindlimbs from E16 BMPR-IICKO and
control embryos that showed the absence of BMPR-II
did not change the timing or extent of cartilage or bone
formation or impact joint morphogenesis (Fig. 2b,c and
data not shown). As endothelial or pulmonary artery
smooth muscle cells with BMPR-II mutations exhibit
increased cell death and failed growth suppression
(Morrell, 2006), we checked for similar alterations in
cell proliferation or apoptosis in BMPR-IICKO femurs but
saw no differences between conditional knockout and
control mice (data not shown). Next, we performed
immunohistochemistry for p-Smad1/5/8 on humeri
from E16 BMPR-IICKO mice and saw no changes in BMP
signaling in chondrocytes, perichondrial, perisoteal, or
bone cells (Fig. 2d,e). Finally, we examined BMPR-II
conditional knockout mice at birth to look for any
defects or fractures in the long bone. Alizarin Red and
Alcian Blue stained skeletal preparation of forelimbs
and hindlimbs from BMPR-IICKO newborns (NB)
showed no significant alterations in bone formation
(Fig. 3a,b), and detailed histological analysis of newborn
BMPR-IICKO long bones confirmed the lack of significant
changes in growth plate, trabecular bone or cortical
bone in the absence of BMPR-II (Fig. 3c,h and data not
shown). We verified these finding by performing in situ
hybridization for chondrocyte and bone markers on
humeri from NB BMR-IICKO mice and saw no alterations
in the levels or localization of Col2a1, Col10a1, or
Osteopontin (Fig. 3d–f,i–k). These data were further
confirmed by using QPCR analysis of RNA from NB
BMPR-IICKO femurs (Fig. 3m). In addition, Von Kossa
staining of femurs from NB mice revealed no changes in
bone mineralization with loss of BMPR-II (Fig. 3g,l).
Taken together, these data confirm our initial observa-
tion that loss of BMPR-II from the early limb does not
impair the level of BMP signaling necessary for endo-
chondral ossification.
Loss of Individual Type II Receptors Does Not
Have Significant Effects on Endochondral Bone
Formation
To confirm the finding that global loss of either of the
Type II BMP receptors, Acvr2a or Acvr2b has little
effect on the limb skeleton (Matzuk et al., 1995; Oh and
Li, 1997), we collected femurs from Acvr2a and Acvr2b
knockout mice at birth and performed a detailed histo-
logical analysis. We found, in agreement with previous
studies, that loss of either Acvr2a or Acvr2b did not
have a significant effect on bone or joint formation
when compared to wild type controls (see Fig. 4).
Taken as a whole the results obtained by analyzing the
limbs of mice lacking each individual Type II BMP re-
ceptor is in keeping with the idea that these Type II
receptors can compensate for one another during limb
skeletogenesis and endochondral bone formation.
Our data, although surprising, are in agreement with
two previous studies on the function of BMPR-II in skel-
FIG. 2. (a) Alizarin Red and Alcian Blue staining of whole skeletons from E16 control and BMPR-IICKO mice. No obvious skeletal patterning
or development differences are detected. (b,c) Toluidine blue staining of distal femurs from E16 mouse embryos showing no obvious differ-
ences between control and BMPR-IICKO bones. (d,e) p-Smad1/5/8 immunohistochemistry of E16 humerus from control and BMPR-IICKO
mice showing no significant changes in BMP R-Smad signaling.
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etal tissues. Mice homozygous for a hypomorphic allele
of BMPR-II die at mid-gestation from cardiovascular
abnormalities but display only a mild axial skeletal phe-
notype of delayed ossification of cervical vertebrae and
interparietal bone and loss of the 13th pair of ribs
(Delot et al., 2003). Transgenic mice engineered to
express a C-terminal truncated form of BMPR-II in
osteoblast lineage cells also only exhibited a mild bone
phenotype of delayed mineralization of the calvaria and
vertebrae at birth (Yang et al., 2010). Taken as a whole,
these data allow us to conclude that BMPR-II is not nec-
essary for endochondral ossification and the require-
ment for BMP signaling may be compensated for by
BMPs acting through Acvr2a and Acvr2b.
METHODS
Mouse Strains
Mice in which Exons 4 and 5 of BMPR-II was flanked
with lox P sites (BMPR-IIf/f) were obtained from Dr.
Hideyuki Beppu, Massachusetts General Hospital, Bos-
ton, MA. The creation and genotyping of the conditional
floxed BMPR-II allele has been described previously
(Beppu et al., 2005). The Prx1-cre allele has also been
described previously (Logan et al., 2002). BMPR-IIf/f
mice were mated to transgenic mice that express Cre
under the control of the Prx1 promoter to create mice
in which BMPR-II is deleted in the early limb mesen-
chyme (BMPR-IICKO).
Acvr2a knockout mice were kindly provided by Dr.
Martin Matzuk (Baylor College of Medicine, Houston,
TX) and described previously (Matzuk et al., 1995).
Acvr2b mice were kindly provided by Dr. Paul Oh (Uni-
versity of Florida College of Medicine, Gainesville, FL)
and described previously (Oh and Li, 1997). All mouse
strains used in this study were on a C57BL/6 3 129/
SvEv mixed genetic background.
Whole Mount and Section In Situ Hybridization
Whole mount in situ hybridization was performed
with digoxygenin-labeled antisense mouse BMPR-II
probe (Beppu et al., 2000) as previously described
(Brent et al., 2003). Section in situ hybridization with
radiolabeled probes was performed as described (Ban-
dyopadhyay et al., 2006). 35S-labeled complementary
RNA probes were transcribed from plasmids encoding
FIG. 3. Long bones of BMPR-IICKO mice have no significant defects in endochondral bone formation. (a,b) Whole mount forelimbs and hin-
dlimbs from newborn control and BMPR-IICKO mice stained with Alizarin Red and Alcian Blue. No fractures or obvious defects in bone
shape, size or formation have developed. Radioactive in situ hybridization analysis of markers for chondrogenesis and osteogenesis on
humeri of newborn control (c–f) and BMPR-IICKO mice (h–k). No changes are detected in Col2a1, Col10a1, or osteopontin. (g,l) Von Kossa
stained sections of distal femur from newborn mice showing no significant differences in mineralization between control and BMPR-IICKO
animals. (m) QPCR analysis of chondrocyte and bone markers in control and BMPR-IICKO femurs at birth. No statistically significant changes
were detected.
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Col2a1 (Kohno et al., 1984), Col10a1 (Jacenko et al.,
1993), and osteopontin (Oldberg et al., 1986).
Skeletal Preparations
For whole skeletal analysis, staged embryos (the day
the vaginal plug was observed was considered embry-
onic day 0.5 - E0.5) and newborn mice were prepared
and stained with Alizarin Red and Alcian Blue to identify
mineralized bone and cartilage as previously described
(McLeod, 1980).
Histological and Immunohistochemical Analysis
For histology, limbs were dissected and fixed in 4%
paraformaldehyde, decalcified in EDTA/PVP when nec-
essary, paraffin embedded, and sectioned. Slides were
stained with Alcian Blue/Fast Red, Toluidine Blue and
Von Kossa using standard methods. For immunofluores-
cence, sections were microwaved in 10 mM citrate
buffer pH 6.0 for antigen retrieval, blocked with 0.5%
bovine serum albumin (BSA) and incubated with phos-
pho-Smad1/5/8 (Cell Signaling Technology) overnight
at 48C. The slides were then washed and incubated
overnight at 48C with Alexa-Fluor-555-conjugated rabbit
secondary antibody (Invitrogen). Apoptosis was eval-
uated using the In Situ Cell Death Detection kit, POD
(Roche). Cell proliferation was analyzed by prolifera-
tion cell nuclear antigen (PCNA) staining using a PCNA
staining kit (Zymed). The PCNA positive or TUNEL pos-
itive cells were individually counted from at least four
sections of comparable regions of the distal femur
growth plate of three control and three BMPR-IICKO lit-
termate pairs at E16.
Western Blots
Western blots were performed on lysates from limb
buds excised from E12.5 control and BMPR-IICKO
embryos. Lysates were resolved on Novex Tris Glycine
gels (Invitrogen) and transferred to Amersham Hybond
ECL nitrocellulose membranes (GE Healthcare).
After blocking in 10% milk, the following primary anti-
bodies were applied overnight at 48C: anti-C-terminal
phospho-Smad1/5/8 (Cell Signaling), anti-C-terminal
phospho-Smad2/3 (Cell Signaling), and anti-Smad1 (Cell
Signaling) rabbit polyclonal antibodies; anti-BMPR-II
(BD Biosciences), anti-Smad2/3 (BD Biosciences), and
anti-b-actin (Sigma) mouse monoclonal antibodies.
Primary antibodies were applied in 5% milk, except for
the detection of phospho-specific isoforms which were
applied in 5% BSA. Appropriate species-specific goat
polyclonal secondary antibodies (anti-mouse: Kirke-
gaard & Perry Laboratories and anti-rabbit: Cell Signal-
ing) were utilized. Immunoblots were developed by
chemiluminscence using Western Lightning (Perkin
Elmer) and exposed to Amersham Hyperfilm ECL (GE
Healthcare).
Quantitative PCR
Total RNA was extracted from E12 embryonic limb
buds and from femurs of newborn mice using Trizol
reagents (Invitrogen) according to the manufacturer’s
protocol. RNA from E12 limb buds was analyzed using
Nanostring nCounter, a novel technology able to mea-
sure directly the number of specific mRNA molecules
without PCR amplification (Geiss et al., 2008). To use
this ultra-sensitive technology, a CodeSet containing
specific probe pairs (reporter and capture probes) for
50 genes was customized. This CodeSet was incubated
at 658C for 19 h with 200 ng of RNA. Immediately after
incubation, the samples were washed and the purified
target/probe complexes were immobilized in a car-
tridge for data collection. The results are expressed in
number of molecules per 200 ng of total RNA. For
Quantitative RT-PCR (QPCR), cDNA was transcribed
from 1 lg of total RNA from NB femurs with random
primer using the Transcriptor First Strand cDNA Synthe-
sis Kit (Roche). QPCR was performed by using the
FIG. 4. Femurs from Acvr2a and Acvr2b knockout mice have no
significant alterations in bone formation. Toluidine blue stained sec-
tions of femurs from newborn wild type (a) and Acvr2a2/2 mice (b)
and newborn wild type (c) and Acvr2b2/2 mice (d).
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Roche LightCycler 480 Real-time PCR system with
probe-based detection (Universal Probe Library; Roche).
Values were normalized to b-actin using the 2-DDCt
method (Livak and Schmittgen, 2001). Experiments
were performed in triplicate.
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